These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37833776)

  • 1. Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.
    Ceriello A; Rodbard HW; Battelino T; Brosius F; Cosentino F; Green J; Ji L; Kellerer M; Koob S; Kosiborod M; Lalic N; Marx N; Nedungadi TP; Parkin CG; Rydén L; Sheu WH; Standl E; Vandvik PO; Schnell O;
    Cardiovasc Diabetol; 2023 Oct; 22(1):277. PubMed ID: 37833776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Shi Q; Nong K; Vandvik PO; Guyatt GH; Schnell O; Rydén L; Marx N; Brosius FC; Mustafa RA; Agarwal A; Zou X; Mao Y; Asadollahifar A; Chowdhury SR; Zhai C; Gupta S; Gao Y; Lima JP; Numata K; Qiao Z; Fan Q; Yang Q; Jin Y; Ge L; Yang Q; Zhu H; Yang F; Chen Z; Lu X; He S; Chen X; Lyu X; An X; Chen Y; Hao Q; Standl E; Siemieniuk R; Agoritsas T; Tian H; Li S
    BMJ; 2023 Apr; 381():e074068. PubMed ID: 37024129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
    Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.
    Frías JP
    Expert Rev Endocrinol Metab; 2020 Nov; 15(6):379-394. PubMed ID: 33030356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
    Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
    Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction.
    Trombara F; Cosentino N; Bonomi A; Ludergnani M; Poggio P; Gionti L; Baviera M; Colacioppo P; Roncaglioni MC; Leoni O; Bortolan F; Agostoni P; Genovese S; Marenzi G
    Cardiovasc Diabetol; 2023 Feb; 22(1):26. PubMed ID: 36747186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.
    McGuire DK; D'Alessio D; Nicholls SJ; Nissen SE; Riesmeyer JS; Pavo I; Sethuraman S; Heilmann CR; Kaiser JJ; Weerakkody GJ
    Cardiovasc Diabetol; 2022 Aug; 21(1):163. PubMed ID: 36002856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
    Baviera M; Foresta A; Colacioppo P; Macaluso G; Roncaglioni MC; Tettamanti M; Fortino I; Genovese S; Caruso I; Giorgino F
    Cardiovasc Diabetol; 2022 Aug; 21(1):162. PubMed ID: 35999556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
    Sohn M; Dietrich JW; Nauck MA; Lim S
    Cardiovasc Diabetol; 2023 Jun; 22(1):153. PubMed ID: 37381019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials.
    Yang Q; Lang Y; Yang W; Yang F; Yang J; Wu Y; Xiao X; Qin C; Zou Y; Zhao Y; Kang D; Liu F
    Diabetes Res Clin Pract; 2023 Apr; 198():110592. PubMed ID: 36842477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY
    Prázný M; Suplotova L; Gumprecht J; Kamenov Z; Fülöp T; Medvedchikov A; Rosenzweig D; Aleksandric M
    Cardiovasc Diabetol; 2022 Oct; 21(1):203. PubMed ID: 36209118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis.
    Oh S; Purja S; Shin H; Kim M; Kim E
    Diab Vasc Dis Res; 2022; 19(3):14791641221106866. PubMed ID: 35686694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).
    Al-Ozairi E; Narula K; Miras AD; Taghadom E; Samad AE; Al Kandari J; Alyosef A; Mashankar A; Al-Najim W; le Roux CW
    Trials; 2024 Feb; 25(1):129. PubMed ID: 38365744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.